Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has been given an average recommendation of "Hold" by the fifteen brokerages that are presently covering the company, Marketbeat.com reports. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $106.23.
A number of research analysts have recently weighed in on the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Cantor Fitzgerald reiterated a "neutral" rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their target price for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Finally, Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th.
Read Our Latest Stock Report on Intra-Cellular Therapies
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. Accredited Wealth Management LLC purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth $28,000. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $32,000. MassMutual Private Wealth & Trust FSB raised its position in shares of Intra-Cellular Therapies by 124.3% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 133 shares during the last quarter. GAMMA Investing LLC lifted its stake in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 240 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies in the 4th quarter worth about $96,000. 92.33% of the stock is owned by institutional investors and hedge funds.
Intra-Cellular Therapies Stock Down 0.0 %
Shares of Intra-Cellular Therapies stock traded down $0.01 during midday trading on Friday, hitting $131.91. The company had a trading volume of 16,062,900 shares, compared to its average volume of 1,464,125. The company has a fifty day simple moving average of $129.43 and a 200 day simple moving average of $100.82. The stock has a market cap of $14.05 billion, a price-to-earnings ratio of -151.62 and a beta of 0.69. Intra-Cellular Therapies has a 12-month low of $64.09 and a 12-month high of $131.98.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. As a group, analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current year.
About Intra-Cellular Therapies
(
Get Free ReportIntra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
See Also
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
